Cytokinetics Inc
(NAS:CYTK)
$
48.3
-0.68 (-1.39%)
Market Cap: 5.06 Bil
Enterprise Value: 5.20 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 43/100 Cytokinetics Inc at UBS BioPharma Conference Transcript
Nov 08, 2023 / 06:00PM GMT
Release Date Price:
$34.76
(-3.04%)
Ashwani Verma
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst
All right. Good day, everybody. My name is Ash Verma. Welcome to UBS Biopharma Conference in Miami. Our next company on the stage is Cytokinetics. And with me, we have Andrew Callos, who will be Chief Commercial Officer; and Fady Malik, who is the EVP of R&D. How are you guys doing today?
Fady Ibraham Malik
Cytokinetics, Incorporated - EVP of Research & Development
Doing well.
Questions & Answers
Ashwani Verma
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst
Great. Thanks for joining us. So since Andrew, you're sitting next to me, so maybe I can start off with some commercial questions first. And I guess maybe just to preface that, like it will be helpful to get a little bit of a background about the story. So if you can just give us a high-level outline for people who might not be familiar about Cytokinetics,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot